Lenperone

Lenperone is a typical antipsychotic medication primarily used in the treatment of schizophrenia and other psychotic disorders. It belongs to the class of drugs known as butyrophenones, which also includes the well-known antipsychotic haloperidol.
Pharmacology[edit]
Lenperone works by blocking dopamine receptors in the brain, particularly the D2 receptors. This action helps to reduce the symptoms of psychosis, such as hallucinations and delusions. The drug may also have some effects on other neurotransmitter systems, including serotonin and norepinephrine.
Indications[edit]
Lenperone is indicated for the treatment of:
- Schizophrenia
- Acute psychosis
- Severe behavioral disorders in adults
Side Effects[edit]
Common side effects of Lenperone include:
- Sedation
- Extrapyramidal symptoms (such as tremors, rigidity, and bradykinesia)
- Weight gain
- Dry mouth
- Constipation
Serious side effects may include:
Contraindications[edit]
Lenperone is contraindicated in individuals with:
- Known hypersensitivity to Lenperone or other butyrophenones
- Severe central nervous system depression
- Parkinson's disease
Dosage[edit]
The dosage of Lenperone varies depending on the condition being treated and the patient's response to the medication. It is typically administered orally, and the dosage is gradually adjusted to achieve the desired therapeutic effect while minimizing side effects.
History[edit]
Lenperone was developed in the mid-20th century as part of the butyrophenone class of antipsychotics. It was introduced as an alternative to other antipsychotic medications with the aim of providing effective treatment for psychotic disorders with a different side effect profile.
See Also[edit]
References[edit]
External Links[edit]
| Lenperone | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
